M&A / Deals LEO Pharma to acquire gene therapy company Replay Pharmaceutical Business ReviewThe acquisition aims to strengthen LEO Pharma's capabilities while leveraging Replay's high payload herpes simplex virus (HSV) delivery vector.Gene Therapy PlatformRead full story pharminent May 1, 2026 (Last updated: May 1, 2026) Pharmaceutical Business Review The acquisition aims to strengthen LEO Pharma’s capabilities while leveraging Replay’s high payload herpes simplex virus (HSV) delivery vector. Gene Therapy Platform Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Eli Lilly lifts 2026 revenue guidance as Q1 marks dominant openingNext: Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitation Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
